Edition:
United States

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

25.21USD
22 Jun 2018
Change (% chg)

$-0.29 (-1.14%)
Prev Close
$25.50
Open
$25.63
Day's High
$25.68
Day's Low
$24.61
Volume
628,907
Avg. Vol
278,220
52-wk High
$43.98
52-wk Low
$13.51

Chart for

About

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without... (more)

Overall

Beta: 1.46
Market Cap(Mil.): $680.22
Shares Outstanding(Mil.): 26.98
Dividend: --
Yield (%): --

Financials

  ADMS.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -5.67 -- --
ROI: -67.05 -5.25 13.10
ROE: -92.17 -6.83 15.09

BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri

* ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

Apr 19 2018

BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment

* 5102 IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT Source text for Eikon: Further company coverage:

Apr 03 2018

BRIEF-Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia

* ADAMAS ANNOUNCES PUBLICATION OF DATA SUPPORTING THE BENEFITS OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

Mar 15 2018

BRIEF-Adamas Pharmaceuticals Says ‍As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers

* ADAMAS PHARMACEUTICALS SAYS ‍AS OF FEB 28, CO RECEIVED PRESCRIPTIONS FOR GOCOVRI FROM ABOUT 390 DISTINCT PRESCRIBERS - SEC FILING​

Mar 12 2018

BRIEF-Adamas Q4 Loss Per Share $1.27

* ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2017

Feb 22 2018

BRIEF-Adamas Announces Proposed Public Offering Of Common Stock

* ADAMAS PHARMACEUTICALS INC SAYS IT PLANS TO OFFER $85 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

Jan 22 2018

BRIEF-Adamas Announces U.S. Commercial Launch Of Gocovri, The First FDA-Approved Medication For Treatment Of Dyskinesia In Parkinson's Disease Patients

* ADAMAS ANNOUNCES U.S. COMMERCIAL LAUNCH OF GOCOVRI™ THE FIRST AND ONLY FDA-APPROVED MEDICATION FOR THE TREATMENT OF DYSKINESIA IN PARKINSON’S DISEASE PATIENTS Source text for Eikon: Further company coverage:

Jan 08 2018

Earnings vs. Estimates